PURPOSE: To evaluate the impact of a predefined gene expression-based classifier for clinical risk estimation and cytotoxic treatment decision making in neuroblastoma patients. PATIENTS AND METHODS: Gene expression profiles of 440 internationally collected neuroblastoma specimens were investigated by microarray analysis, 125 of which were examined prospectively. Patients were classified as either favorable or unfavorable by a 144-gene prediction analysis for microarrays (PAM) classifier established previously on a separate set of 77 patients. PAM classification results were compared with those of current prognostic markers and risk estimation strategies. RESULTS: The PAM classifier reliably distinguished patients with contrasting clinical courses (favorable [n = 249] and unfavorable [n = 191]; 5-year event free survival [EFS] 0.84 +/- 0.03 v 0.38 +/- 0.04; 5-year overall survival [OS] 0.98 +/- 0.01 v 0.56 +/- 0.05, respectively; both P < .001). Moreover, patients with divergent outcome were robustly discriminated in both German and international cohorts and in prospectively analyzed samples (P <or= .001 for both EFS and OS for each). In subgroups with clinical low-, intermediate-, and high-risk of death from disease, the PAM predictor significantly separated patients with divergent outcome (low-risk 5-year OS: 1.0 v 0.75 +/- 0.10, P < .001; intermediate-risk: 1.0 v 0.82 +/- 0.08, P = .042; and high-risk: 0.81 +/- 0.08 v 0.43 +/- 0.05, P = .001). In multivariate Cox regression models based on both EFS and OS, PAM was a significant independent prognostic marker (EFS: hazard ratio [HR], 3.375; 95% CI, 2.075 to 5.492; P < .001; OS: HR, 11.119, 95% CI, 2.487 to 49.701; P < .001). The highest potential clinical impact of the classifier was observed in patients currently considered as non-high-risk (n = 289; 5-year EFS: 0.87 +/- 0.02 v 0.44 +/- 0.07; 5-year OS: 1.0 v 0.80 +/- 0.06; both P < .001). CONCLUSION: Gene expression-based classification using the 144-gene PAM predictor can contribute to improved treatment stratification of neuroblastoma patients.
PURPOSE: To evaluate the impact of a predefined gene expression-based classifier for clinical risk estimation and cytotoxic treatment decision making in neuroblastomapatients. PATIENTS AND METHODS: Gene expression profiles of 440 internationally collected neuroblastoma specimens were investigated by microarray analysis, 125 of which were examined prospectively. Patients were classified as either favorable or unfavorable by a 144-gene prediction analysis for microarrays (PAM) classifier established previously on a separate set of 77 patients. PAM classification results were compared with those of current prognostic markers and risk estimation strategies. RESULTS: The PAM classifier reliably distinguished patients with contrasting clinical courses (favorable [n = 249] and unfavorable [n = 191]; 5-year event free survival [EFS] 0.84 +/- 0.03 v 0.38 +/- 0.04; 5-year overall survival [OS] 0.98 +/- 0.01 v 0.56 +/- 0.05, respectively; both P < .001). Moreover, patients with divergent outcome were robustly discriminated in both German and international cohorts and in prospectively analyzed samples (P <or= .001 for both EFS and OS for each). In subgroups with clinical low-, intermediate-, and high-risk of death from disease, the PAM predictor significantly separated patients with divergent outcome (low-risk 5-year OS: 1.0 v 0.75 +/- 0.10, P < .001; intermediate-risk: 1.0 v 0.82 +/- 0.08, P = .042; and high-risk: 0.81 +/- 0.08 v 0.43 +/- 0.05, P = .001). In multivariate Cox regression models based on both EFS and OS, PAM was a significant independent prognostic marker (EFS: hazard ratio [HR], 3.375; 95% CI, 2.075 to 5.492; P < .001; OS: HR, 11.119, 95% CI, 2.487 to 49.701; P < .001). The highest potential clinical impact of the classifier was observed in patients currently considered as non-high-risk (n = 289; 5-year EFS: 0.87 +/- 0.02 v 0.44 +/- 0.07; 5-year OS: 1.0 v 0.80 +/- 0.06; both P < .001). CONCLUSION: Gene expression-based classification using the 144-gene PAM predictor can contribute to improved treatment stratification of neuroblastomapatients.
Authors: Thomas P Stricker; Andres Morales La Madrid; Alexandre Chlenski; Lisa Guerrero; Helen R Salwen; Yasmin Gosiengfiao; Elizabeth J Perlman; Wayne Furman; Armita Bahrami; Jason M Shohet; Peter E Zage; M John Hicks; Hiroyuki Shimada; Rie Suganuma; Julie R Park; Sara So; Wendy B London; Peter Pytel; Kirsteen H Maclean; Susan L Cohn Journal: Mol Oncol Date: 2014-01-31 Impact factor: 6.603
Authors: Robert W Schnepp; Priya Khurana; Edward F Attiyeh; Pichai Raman; Sara E Chodosh; Derek A Oldridge; Maria E Gagliardi; Karina L Conkrite; Shahab Asgharzadeh; Robert C Seeger; Blair B Madison; Anil K Rustgi; John M Maris; Sharon J Diskin Journal: Cancer Cell Date: 2015-10-17 Impact factor: 31.743
Authors: Katleen De Preter; Pieter Mestdagh; Joëlle Vermeulen; Fjoralba Zeka; Arlene Naranjo; Isabella Bray; Victoria Castel; Caifu Chen; Elzbieta Drozynska; Angelika Eggert; Michael D Hogarty; Ewa Izycka-Swieszewska; Wendy B London; Rosa Noguera; Marta Piqueras; Kenneth Bryan; Benjamin Schowe; Peter van Sluis; Jan J Molenaar; Alexander Schramm; Johannes H Schulte; Raymond L Stallings; Rogier Versteeg; Geneviève Laureys; Nadine Van Roy; Frank Speleman; Jo Vandesompele Journal: Clin Cancer Res Date: 2011-10-26 Impact factor: 12.531
Authors: Elizabeth Sokol; Ami V Desai; Mark A Applebaum; Dominique Valteau-Couanet; Julie R Park; Andrew D J Pearson; Gudrun Schleiermacher; Meredith S Irwin; Michael Hogarty; Arlene Naranjo; Samuel Volchenboum; Susan L Cohn; Wendy B London Journal: J Clin Oncol Date: 2020-04-21 Impact factor: 44.544
Authors: Kristoffer von Stedingk; Jan Koster; Marta Piqueras; Rosa Noguera; Samuel Navarro; Sven Påhlman; Rogier Versteeg; Ingrid Ora; David Gisselsson; David Lindgren; Håkan Axelson Journal: Transl Oncol Date: 2013-08-01 Impact factor: 4.243
Authors: Shahab Asgharzadeh; Jill A Salo; Lingyun Ji; André Oberthuer; Matthias Fischer; Frank Berthold; Michael Hadjidaniel; Cathy Wei-Yao Liu; Leonid S Metelitsa; Roger Pique-Regi; Peter Wakamatsu; Judith G Villablanca; Susan G Kreissman; Katherine K Matthay; Hiroyuki Shimada; Wendy B London; Richard Sposto; Robert C Seeger Journal: J Clin Oncol Date: 2012-08-27 Impact factor: 44.544
Authors: Navin R Pinto; Mark A Applebaum; Samuel L Volchenboum; Katherine K Matthay; Wendy B London; Peter F Ambros; Akira Nakagawara; Frank Berthold; Gudrun Schleiermacher; Julie R Park; Dominique Valteau-Couanet; Andrew D J Pearson; Susan L Cohn Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544